Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
Open accessThe DOI matches its Crossref record; 34 of the 36 references it cites were found in a registry or an index.
Abstract
Introduction: PROOF (a Prospective Observational Registry to Describe the Disease Course and Outcomes of Idiopathic Pulmonary Fibrosis) is an ongoing, observational registry initiated in 2013 with the aim of collecting real-world data from patients with idiopathic pulmonary fibrosis (IPF). Here, we present comprehensive baseline data, which were collected from patients on registry inclusion. Methods: Patients with IPF were enrolled across eight centres in Belgium and Luxembourg. Baseline data collected included demographics, diagnostic information and clinical characteristics, including lung function and health-related quality of life. Data on comorbidities and prescribed medication were also collected. Results: A total of 277 patients were enrolled in the PROOF registry. At inclusion, 92.8% and 6.5% of patients had a definite or probable diagnosis of IPF, respectively. Mean per cent predicted forced vital capacity and carbon monoxide diffusing capacity were 80.6% and 46.9%, respectively. Mean St. George’s Respiratory Questionnaire total score was 47.0, and mean Cough-Visual Analogue Scale score was 30.5 mm. The most prevalent comorbidities reported at inclusion were gastrointestinal disorders (50.2%), including gastro-oesophageal reflux disease (47.3%) and metabolism and nutrition disorders (39.7%). At inclusion, 67.2% and 2.2% of patients were prescribed pirfenidone and nintedanib, respectively, with treatment initiated either prior to, or at the time of, inclusion. Medication prescribed concomitantly with pirfenidone included antihypertensives (54.8%), statins (37.1%) and prophylactic antithrombotics/anticoagulants (36.6%). Conclusion: The PROOF registry provides valuable demographic and clinical data from a real-world population of patients with IPF in Belgium and Luxembourg, demonstrating the high burden of comorbidities and prescribed medication in these patients. Longitudinal data from this patient population will be investigated in future analyses. Trial registration: PROOF is registered with the relevant authorities in Belgium and Luxembourg, with registration to Comité National d’Éthique et de Recherché (CNER) N201309/03 – 12 September 2013 and a notification to Comité National de Protection des Données (CNDP).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654 · cited 1×
“Similarly, in the INPULSIS trials of nintedanib (INPULSIS 1 and 2: 52 Weeks, Double Blind, Randomized, Placebo-controlled Trials Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis; NCT01335464 and NCT01335477), nintedanib…”
MethodDiagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1255st · Cited by 4,103 · cited 1×
“recommendation that has provoked much discussion.(31) 32 These changes in diagnostic practice over time and variations in interpretation are likely to affect comparisons between real-world populations, particularly in countries including Belgium where diagnosis of IPF with a high CI is necessary (and was necessary at…”
BackgroundPirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765 · cited 1×
“IntroductIon Idiopathic pulmonary fibrosis (IPF) is a debilitating, irreversible, fatal, fibrosing lung disease.(1) 2 Progressive symptoms including cough and shortness of breath lead to increasing limitations on daily activities and a growing dependence on family or caregivers.”
BackgroundA Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis
Ley, B., Ryerson, C. J., Vittinghoff, E., Ryu, J. H., Tomassetti, S., Lee, J. S., Poletti, V., Buccioli, M., Elicker, B. M., Jones, K. D., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-10-201205150-00004 · Cited by 1,308 · cited 2×
“Other clinical assessments included 6 min walk distance (6MWD) and the Gender, Age and Physiology (GAP) Index.(18) Self-reported HRQoL, generic health status and cough severity were assessed using the St.”
MethodDiagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper
Lynch, D. A., Sverzellati, N., Travis, W. D., Brown, K. K., Colby, T. V., Galvin, J. R., Goldin, J. G., Hansell, D. M., Inoue, Y., Johkoh, T., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30433-2 · Cited by 1,030 · cited 1×
“In these cases, a surgical lung biopsy is not required.(30) However, the 2018 international diagnostic guidelines provide a conditional recommendation for surgical lung biopsy in patients with probable UIP, a”
BackgroundERS guidelines on the assessment of cough
Morice, A. H., Fontana, G. A., Belvisi, M. G., Birring, S. S., Chung, K. F., Dicpinigaitis, P. V., Kastelik, J. A., McGarvey, L. P., Smith, J. A., Tatar, M., et al. (2007) · European Respiratory Journal · doi:10.1183/09031936.00101006 · Cited by 693
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., du Bois, R. M., Fagan, E. A., Fishman, R. S., Glaspole, I., Glassberg, M. K., Lancaster, L., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00026-2015 · Cited by 468 · cited 1×
“Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis; NCT00287716 and NCT00287729), pirfenidone significantly reduced lung function decline versus placebo over 52 weeks.(9) Similarly, in the INPULSIS trials of nintedanib (INPULSIS 1 and 2: 52 Weeks, Double Blind, Randomized, Placebo-controlled Trials Evaluating…”
BackgroundInterpretation of quality of life scores from the St George's Respiratory Questionnaire
Ferrer, M., Villasante, C., Alonso, J., Sobradillo, V., Gabriel, R., Vilagut, G., Masa, J. F., Viejo, J. L., Jiménez-Ruiz, C. A., & Miravitlles, M. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00213202 · Cited by 311 · cited 1×
“Scores are weighted to provide a total score from 0 to 100, with higher scores indicating greater impairment.(19) 22 23 The EQ-VAS was used by patients to rate their overall health status on a linear visual scale, with 0 mm representing ‘worst health imaginable’ and 100 mm representing ‘best health imaginable’.”
MethodBehr, J., Kreuter, M., Hoeper, M. M., Wirtz, H., Klotsche, J., Koschel, D., Andreas, S., Claussen, M., Grohé, C., Wilkens, H., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00217614 · Cited by 247
Jo, H. E., Glaspole, I., Grainge, C., Goh, N., Hopkins, P. M. A., Moodley, Y., Reynolds, P. N., Chapman, S., Walters, E. H., Zappala, C., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.01592-2016 · Cited by 233 · cited 6×
“For example, in both the Australian IPF registry and the INSIGHTS-IPF registry, pulmonary hypertension at baseline was suspected or confirmed in nearly 20% of patients compared with only 4% in PROOF.28 33 It is possible that the observed differences in the prevalence of pulmonary hypertension might be partially explai…”
BackgroundResultInfluentialKreuter, M., Swigris, J., Pittrow, D., Geier, S., Klotsche, J., Prasse, A., Wirtz, H., Koschel, D., Andreas, S., Claussen, M., et al. (2017) · Respiratory Research · doi:10.1186/s12931-017-0621-y · Cited by 210 · cited 9×
“Misdiagnosis with other respiratory disorders has also been identified as a key reason for delayed diagnosis of IPF.5 Indeed, in the PROOF registry, the non-specific symptoms of cough and breathlessness were present at baseline in 66.8% and 67.9% of patients, respectively.”
MethodInfluentialVelcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis?
Cottin, V., & Cordier, J.-F. (2012) · European Respiratory Journal · doi:10.1183/09031936.00001612 · Cited by 178
Yorke, J., Jones, P. W., & Swigris, J. J. (2010) · Thorax · doi:10.1136/thx.2010.139121 · Cited by 147
European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers
Bonella, F., Wijsenbeek, M., Molina-Molina, M., Duck, A., Mele, R., Geissler, K., & Wuyts, W. (2016) · European Respiratory Journal · doi:10.1183/13993003.01204-2015 · Cited by 144
Self-citationGlaspole, I. N., Chapman, S. A., Cooper, W. A., Ellis, S. J., Goh, N. S., Hopkins, P. M., Macansh, S., Mahar, A., Moodley, Y. P., Paul, E., et al. (2017) · Respirology · doi:10.1111/resp.12989 · Cited by 123
Cough in idiopathic pulmonary fibrosis
van Manen, M. J. G., Birring, S. S., Vancheri, C., Cottin, V., Renzoni, E. A., Russell, A.-M., & Wijsenbeek, M. S. (2016) · European Respiratory Review · doi:10.1183/16000617.0090-2015 · Cited by 114
Russell, A.-M., Ripamonti, E., & Vancheri, C. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0171-y · Cited by 111 · cited 9×
“Misdiagnosis with other respiratory disorders has also been identified as a key reason for delayed diagnosis of IPF.5 Indeed, in the PROOF registry, the non-specific symptoms of cough and breathlessness were present at baseline in 66.8% and 67.9% of patients, respectively.”
BackgroundInfluentialThe lived experience with idiopathic pulmonary fibrosis: a qualitative study
Overgaard, D., Kaldan, G., Marsaa, K., Nielsen, T. L., Shaker, S. B., & Egerod, I. (2016) · European Respiratory Journal · doi:10.1183/13993003.01566-2015 · Cited by 109
Maher, T. M., Molina-Molina, M., Russell, A.-M., Bonella, F., Jouneau, S., Ripamonti, E., Axmann, J., & Vancheri, C. (2017) · BMC Pulmonary Medicine · doi:10.1186/s12890-017-0468-5 · Cited by 108
Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
Kreuter, M., Bonella, F., Maher, T. M., Costabel, U., Spagnolo, P., Weycker, D., Kirchgaessler, K.-U., & Kolb, M. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-208819 · Cited by 85
Self-citationBelkin, A., Albright, K., & Swigris, J. J. (2014) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2013-000007 · Cited by 83
Kreuter, M., Wijsenbeek, M. S., Vasakova, M., Spagnolo, P., Kolb, M., Costabel, U., Weycker, D., Kirchgaessler, K.-U., & Maher, T. M. (2016) · European Respiratory Journal · doi:10.1183/13993003.02087-2015 · Cited by 70 · cited 1×
“Based on previous research investigating clinical outcomes in patients with IPF enrolled in the placebo arms of ASCEND or CAPACITY who were treated with anticoagulants or statins for non-IPF indications, these post-hoc analyses have suggested that while statins may have some beneficial effects on disease-related outco…”
MethodSelf-citationSwigris, J. J., Esser, D., Wilson, H., Conoscenti, C., Schmidt, H., Stansen, W., Leidy, N. K., & Brown, K. K. (2016) · European Respiratory Journal · doi:10.1183/13993003.01788-2016 · Cited by 58
Kaunisto, J., Kelloniemi, K., Sutinen, E., Hodgson, U., Piilonen, A., Kaarteenaho, R., Mäkitaro, R., Purokivi, M., Lappi-Blanco, E., Saarelainen, S., et al. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0074-3 · Cited by 53
Ferrara, G., Carlson, L., Palm, A., Einarsson, J., Olivesten, C., Sköld, M., & Pulmonar, F. T. S. I. (2016) · European Clinical Respiratory Journal · doi:10.3402/ecrj.v3.31090 · Cited by 43
Salisbury, M. L., Tolle, L. B., Xia, M., Murray, S., Tayob, N., Nambiar, A. M., Schmidt, S. L., Lagstein, A., Myers, J. L., Gross, B. H., et al. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.08.025 · Cited by 37 · cited 1×
“The high biopsy rate observed in the PROOF registry may be partially explained by evidence suggesting that patients with less advanced IPF are less likely to demonstrate definite UIP on HRCT at the time of diagnosis.(29) The potential relationship between less advanced disease and the likelihood of definite UIP on HRC…”
BackgroundWilson, J. W., du Bois, R. M., & King, T. E. (2008) · Thorax · doi:10.1136/thx.2004.031062 · Cited by 27
A global registry for idiopathic pulmonary fibrosis: the time is now
Ryerson, C. J., Corte, T. J., Collard, H. R., & Richeldi, L. (2014) · European Respiratory Journal · doi:10.1183/09031936.00051914 · Cited by 27
IPF diagnosis: flexibility is a virtue
Wells, A. U. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30374-6 · Cited by 16
The future of the development of medicines in idiopathic pulmonary fibrosis
Fregonese, L., & Eichler, I. (2015) · BMC Medicine · doi:10.1186/s12916-015-0480-7 · Cited by 14
Analysis of comorbid conditions in 1210 IPF patients from the EMPIRE registry
Jovanović, D. M., Moğulkoç, N., Šterclová, M., Żołnowska, B., Bartoš, V., Plačková, M., Müller, V., Lacina, L., Slivka, R., Doubková, M., et al. (2017) · European Respiratory Journal · doi:10.1183/1393003.congress-2017.oa1953 · Cited by 3 · cited 1×
“However, real-world evidence suggests that comorbid conditions are prevalent in patients with IPF in clinical practice, with results from the European MultiPartner IPF Registry (EMPIRE) reporting that 86% of patients with IPF had a comorbid diagnosis.(13) These data suggest that there is a need to further investigate…”
Result
Research works printed but not linked: 3
- King TE, Bradford WZ, Castro-Bernardini S The ASCEND study: a randomized, double-blind, placebo controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF). American Thoracic Society International Conference, 2014.
- Wuyts W, Dahlqvist C, Slabbynck H Demographics and healthcare utilization of patients with idiopathic pulmonary fibrosis (IPF) in a real-world setting: updated findings from 277 patients in the PROOF registry. Abstract A1127 American Thoracic Society International Conference, 2017.
- Flaherty K, de Andrade J, Chou W Baselinecharacteristics of the initial 200 participants in the Pulmonary Fibrosis Foundation Registry. Abstract A24 American Thoracic Society International Conference, 2017.
Cited by
Pulmonary fibrosis: from pathogenesis to clinical decision-making
Koudstaal, T., Funke-Chambour, M., Kreuter, M., Molyneaux, P. L., & Wijsenbeek, M. S. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.08.010 · Cited by 256
Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)
Nasser, M., Larrieu, S., Si-Mohamed, S., Ahmad, K., Boussel, L., Brevet, M., Chalabreysse, L., Fabre, C., Marque, S., Revel, D., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.02718-2020 · Cited by 217
Behr, J., Prasse, A., Wirtz, H., Koschel, D., Pittrow, D., Held, M., Klotsche, J., Andreas, S., Claussen, M., Grohé, C., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02279-2019 · Cited by 198
Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue
Caminati, A., Lonati, C., Cassandro, R., Elia, D., Pelosi, G., Torre, O., Zompatori, M., Uslenghi, E., & Harari, S. A. (2019) · European Respiratory Review · doi:10.1183/16000617.0044-2019 · Cited by 139
Idiopathic pulmonary fibrosis.
Koudstaal, T., & Wijsenbeek, M. S. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104166 · Cited by 105
Metadata
- Authors
- Wuyts, W. A., Dahlqvist, C., Slabbynck, H., Schlesser, M., Gusbin, N., Compere, C., Maddens, S., Kirchgaessler, K.-U., Bartley, K., & Bondue, B.
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- CHU Dinant Godinne UCL Namur (BE)
- ZNA Middelheim Hospital (BE)
- Centre Hospitalier de Luxembourg (LU)
- Centre hospitalier régional de la Citadelle (BE)
- CHIREC Hospital, Brussels, Belgium
- AZ Groeninge (BE)
- F. Hoffmann-La Roche AG (CH)
- Genentech (US)
- Erasmus Hospital (BE)
- Corresponding author
- Wuyts, Wim A
- Venue
- BMJ Open Respiratory Research
- Publisher
- BMJ
- Published
- 2018-11
- Volume
- 5
- Issue
- 1
- Pages
- e000331
- ISSN
- 2052-4439 (ISSN-L)
- PMC
- PMC6267319
- OpenAlex
- W2900996054
- Cited by
- 54
- References
- 36
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 2 · 2023: 6 · 2022: 13 · 2021: 7 · 2020: 14 · 2019: 5
- FWCI
- 4.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open Respiratory Research (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DIAL (Catholic University of Leuven) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Funders
- Genentech, Inc. and F. Hoffmann-La Roche, Ltd.
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, comorbidities, prescription drugs, pirfenidone, nintedanib, lung function, health-related quality of life, gastroesophageal reflux disease, disease burden, real-world data, Belgium, Luxembourg, statins, antihypertensive drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
